Informing Your Future Clozapine Patients of the Mortality Risk: Fear of Agranulocytosis vs. Pharmacovigilance Fatal Outcomes

Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Emilio J. Sanz; Carlos De las Cuevas

doi:10.62641/aep.2486

Authors

Jose de Leon Mental Health Research Center at Eastern State Hospital, Lexington, KY 40511, USA; Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, 01006 Vitoria, Spain https://orcid.org/0000-0002-7756-2314
Can-Jun Ruan The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, 100088 Beijing, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, 100088 Beijing, China https://orcid.org/0000-0002-1625-7367
Georgios Schoretsanitis Department of Psychiatry, Lausanne University Hospital and University of Lausanne, CH-1008 Prilly Lausanne, Switzerland; Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, CH-1005 Lausanne, Switzerland; The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY 11004, USA; Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY 11549, USA https://orcid.org/0000-0002-3851-4117
Emilio J. Sanz Department of Physical Medicine and Pharmacology, School of Medicine, University of La Laguna, 38200 Tenerife, Canary Islands, Spain; Hospital Universitario de Canarias, 38320 Tenerife, Spain https://orcid.org/0000-0001-6788-4435
Carlos De las Cuevas Department of Internal Medicine, Dermatology and Psychiatry, School of Medicine, and Instituto Universitario de Neurociencia (IUNE), University of La Laguna, 38200 Tenerife, Canary Islands, Spain https://orcid.org/0000-0001-5742-905X